RxDoctor Payments Data

Howard Pitchon, MD

Infectious Disease · Beverly Hills, CANPI 1396968376

Payments from drug & device makers

$514in general payments, 2019–2025

Across 20 payments — averaging $25.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$189
  • Insmed, Inc.$126
  • ANI Pharmaceuticals, Inc.$95
  • Viiv Healthcare Company$59
  • Exact Sciences$29
  • Merck$17

What the payments were for

  • Food & beverage$42382%
  • Education$9118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$514 in reported general payments places this provider in the 50th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$112,673
Medicare patients
168
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DescovyEmtricitabine/Tenofov Alafenam70$160,358
TivicayDolutegravir Sodium45$113,522
BiktarvyBictegrav/Emtricit/Tenofov Ala24$90,706
TriumeqAbacavir/Dolutegravir/Lamivudi17$65,313
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$45,778
OzempicSemaglutide21$19,359
JanuviaSitagliptin Phosphate11$6,343
VascepaIcosapent Ethyl17$5,644
Testosterone18$4,130
Oxycodone Hcl102$3,731
Abacavir-LamivudineAbacavir Sulfate/Lamivudine12$3,346
Atazanavir Sulfate11$2,914
Famciclovir13$2,350
Methenamine Hippurate38$2,123
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$2,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay, Triumeq$59$178,83462 claims
MerckJanuvia$17$6,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 856 infectious disease providers in California.

Other infectious disease in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →